Altered localization of a coactivator sensitizes breast cancer cells to tumor necrosis factor–induced apoptosis

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2006-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-05-0276PMID 16505095
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells.

  2005cited by this paper
• Novel estrogen receptor coactivator PELP1/MNAR gene and ERbeta expression in salivary duct adenocarcinoma: potential therapeutic targets.

  2005cited by this paper
• Tumor necrosis factor, cancer and anticancer therapy.

  2005cited by this paper
• The NFkappaB pathway and endocrine-resistant breast cancer.

  2005cited by this paper
• Effect of low-dose tumor necrosis factor-alpha in combination with STEALTH liposomal cisplatin (SPI-077) on soft-tissue- and osteosarcoma-bearing rats.

  2005cited by this paper
• IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW，Thompson RW，et al//Proc Natl Acad Sci U S A

  2005cited by this paper
• The NFκB pathway and endocrine-resistant breast cancer

  2005cited by this paper
• The nuclear factor κB inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)–induced apoptosis in antiestrogen-resistant breast cancer cells

  2005cited by this paper
• Functional implications of altered subcellular localization of PELP1 in breast cancer cells.

  2005cited by this paper
• Nuclear factor-κB inhibitors as sensitizers to anticancer drugs

  2005cited by this paper
• Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs.

  2005cited by this paper
• Hyperthermic Isolated Perfusion With Low-Dose Tumor Necrosis Factor α and Doxorubicin for the Treatment of Limb-Threatening Soft Tissue Sarcomas

  2005cited by this paper
• Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas.

  2005cited by this paper
• Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity.

  2004cited by this paper
• Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells

  2004cited by this paper
• Coupling Tumor Necrosis Factor-α with αV Integrin Ligands Improves Its Antineoplastic Activity

  2004cited by this paper
• Nuclear factor-κB: a friend or a foe in cancer?

  2004cited by this paper
• Nuclear factor-κB: The enemy within

  2004cited by this paper
• Potential Role of a Novel Transcriptional Coactivator PELP1 in Histone H1 Displacement in Cancer Cells

  2004cited by this paper
• Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs.

  2004cited by this paper
• TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors.

  2004cited by this paper
• Nuclear factor-kappaB: the enemy within.

  2004cited by this paper
• Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors.

  2004cited by this paper
• Novel estrogen receptor coregulators and signaling molecules in human diseases

  2004cited by this paper
• Tumor Vascular Targeting with Tumor Necrosis Factor α and Chemotherapeutic Drugs

  2004cited by this paper
• Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

  2004cited by this paper
• Cloning and functional characterization of PELP1/MNAR promoter.

  2004cited by this paper
• Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

  2003cited by this paper
• Nongenomic actions of steroid hormones

  2003cited by this paper
• Cyclin E overexpression enhances cytokine-mediated apoptosis in MCF7 breast cancer cells

  2003cited by this paper
• Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.

  2003cited by this paper
• Biological functions of tumor necrosis factor cytokines and their receptors.

  2003cited by this paper
• Estrogen Withdrawal-Induced NF-κB Activity and Bcl-3 Expression in Breast Cancer Cells: Roles in Growth and Hormone Independence

  2003cited by this paper
• Clinical Significance of AIB1 Expression in Human Breast Cancer

  2003cited by this paper
• Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.

  2003cited by this paper
• Selective targeted delivery of TNFalpha to tumor blood vessels.

  2003cited by this paper
• Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: Ten years of successful antivascular therapy

  2003cited by this paper
• Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780).

  2002cited by this paper
• Genomic and nongenomic effects of estrogen in the vasculature.

  2002cited by this paper
• Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.

  2002cited by this paper
• Estrogen receptor: current understanding of its activation and modulation.

  2001cited by this paper
• Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor alpha.

  2001cited by this paper
• Molecular Cloning and Characterization of PELP1, a Novel Human Coregulator of Estrogen Receptor α

  2001cited by this paper
• Cellular and molecular pharmacology of antiestrogen action and resistance.

  2001cited by this paper
• Molecular and pharmacological aspects of antiestrogen resistance.

  2001cited by this paper
• Thoughts on tamoxifen resistant breast cancer. Are coregulators the answer or just a red herring?

  2000cited by this paper
• Selective estrogen receptor modulators: structure, function, and clinical use.

  2000cited by this paper
• Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer.

  2000cited by this paper
• Death receptors: signaling and modulation.

  1998cited by this paper
• Nongenomic actions of steroid hormones in reproductive tissues.

  1998cited by this paper
• Bax directly induces release of cytochrome c from isolated mitochondria.

  1998cited by this paper
• Apoptosis: Activate NF-κB or die?

  1997cited by this paper
• Caspases: the executioners of apoptosis.

  1997cited by this paper
• Activate NF-kappa B or die?

  1997cited by this paper
• Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth

  1997cited by this paper
• Alteration of the Sphingomyelin/Ceramide Pathway Is Associated with Resistance of Human Breast Carcinoma MCF7 Cells to Tumor Necrosis Factor-α-mediated Cytotoxicity*

  1997cited by this paper
• Suppression of TNF-alpha-induced apoptosis by NF-kappaB.

  1996cited by this paper
• Tumor necrosis factor α is a powerful apoptotic inducer in lymphoid leukemic cells expressing the P‐170 glycoprotein

  1996cited by this paper
• Suppression of TNF-α-Induced Apoptosis by NF-κB

  1996cited by this paper
• Effects of tumor necrosis factor-alpha on antimitogenicity and cell cycle-related proteins in MCF-7 cells.

  1995cited by this paper
• Possible mechanisms in the emergence of tamoxifen-resistant breast cancer.

  1995cited by this paper
• Caffeine potentiates the lethality of tumour necrosis factor in cancer cells.

  1993cited by this paper
• Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity.

  1987cited by this paper
• This is an author version of the contribution published on: Questa è la versione dell’autore dell’opera: Selective targeted delivery of TNFα to tumor blood vessels

  year unknowncited by this paper
• highlighted topics Genome and Hormones: Gender Differences in Physiology Invited Review: Cell localization, physiology, and nongenomic actions of estrogen receptors

  year unknowncited by this paper

• The 'dark side' of tamoxifen : understanding adverse cellular response to endocrine therapy in ER+ breast cancer

  2019cites this paper
• Cytoplasmic Localization of Proline, Glutamic Acid, Leucine-rich Protein 1 (PELP1) Induces Breast Epithelial Cell Migration through Up-regulation of Inhibitor of κB Kinase ϵ and Inflammatory Cross-talk with Macrophages*

  2016cites this paper
• Minireview: Deciphering the Cellular Functions of PELP1.

  2015cites this paper
• PELP1: a review of PELP1 interactions, signaling, and biology.

  2014influential citation
• Award Number: W81XWH-08-1-0604 TITLE: Hormonal Resistance and Metastasis: ER-coregulator-Src Signaling Targeted therapy

  2010cites this paper
• Regulation of ERα-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: Implications for breast cancer cell survival

  2010cites this paper
• Hormonal Resistance And Metastasis ER-Coregulartor-Src Signaling Targeted Therapy

  2010cites this paper
• Regulation of ERalpha-mediated transcription of Bcl-2 by PI3K-AKT crosstalk: implications for breast cancer cell survival.

  2010cites this paper
• Expression of ERα, ERβ and Co-Regulator PELP1/MNAR in Colorectal Cancer: Prognostic Significance and Clinicopathologic Correlations

  2009cites this paper
• PELP1: A novel therapeutic target for hormonal cancers

  2009cites this paper
• Emerging significance of ER-coregulator PELP1/MNAR in cancer.

  2007cites this paper
• Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR

  2007cites this paper
• Radiation-induced apoptosis along with local and systemic cytokine elaboration is associated with DC plus radiotherapy-mediated renal cell tumor regression.

  2007cites this paper
• Award Number: W81XWH-06-1-0398 TITLE: Role of PELP1 in EGFR-ER Signaling Crosstalk in Ovarian Cancer Cells

  2007cites this paper
• Basic science (February 2006)

  2006cites this paper
• Comprehensive Analysis of Recent Biochemical and Biologic Findings Regarding a Newly Discovered Protein-PELP1/MNAR

  2006cites this paper
• Essential Role of KIBRA in Co-activator Function of Dynein Light Chain 1 in Mammalian Cells*

  2006cites this paper